Blocking the PI3K/Akt/mTOR pathway (which indirectly activates HIF1α), with the inhibitor, temsirolimus has shown promise in vitro and in phase II clinical trials against breast cancer [115,117]. This evidence concerns the gene HIF1A and breast carcinoma.